Emergent BioSolutions (EBS) News Today

Emergent BioSolutions (NYSE:EBS) Sets New 1-Year High at $13.23

BNP Paribas Financial Markets raised its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 155.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 163,589 shares of the biopharmaceutical company's stock after buying a

Emergent BioSolutions (NYSE:EBS) Shares Up 4.9%

Emergent BioSolutions (NYSE:EBS) Stock Price Down 3%

Recent market rotations and sector-specific outflows have created a ripe environment for potential pullbacks despite the market's 17% YTD gain.

Emergent BioSolutions (NYSE:EBS) Hits New 52-Week High at $12.74

Susquehanna Fundamental Investments LLC bought a new position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 118,647 shares of the biopharmaceutical company's

Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 5,190,000 shares, a decline of 18.0% from the June 15th total of 6,330,000 shares. Based on an average trading volume of 4,880,000 shares, the short-interest ratio is presently 1.1 days. Approximately 10.3% of the shares of the stock are sold short.

Emergent BioSolutions (NYSE:EBS) Trading 7.7% Higher

Benchmark reissued a "buy" rating and set a $8.00 price objective on shares of Emergent BioSolutions in a report on Tuesday.

Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report) Director Kathryn C. Zoon sold 10,000 shares of the stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the transaction, the director now owns 54,482 shares of the company's stock, valued at approximately $332,885.02. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report) was the recipient of some unusual options trading on Thursday. Stock traders purchased 5,129 put options on the company. This is an increase of approximately 305% compared to the average volume of 1,265 put options.

Charles Schwab Investment Management Inc. boosted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 84.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,873,984 shares of the biopharmaceutic